Malaria Mosquito Bites Turned Into Immune Boosters in New Chemovaccination Strategy

Over six hundred thousand malaria fatalities occur annually, primarily affecting pregnant women and young children, with an alarming death rate of one child in Africa per minute. Malaria's progression involves Plasmodium parasites multiplying and maturing in the liver before infecting red blood cells, resulting in the disease's symptoms.

Traditional vaccines aiming to curb infection during the liver stage of Plasmodium infection face challenges such as complex production and repeated intravenous administrations in field conditions. Furthermore, drug resistance poses a significant threat to malaria control, necessitating novel strategies to halt infection.

Researchers from WEHI in Melbourne, Australia, have successfully developed a pioneering immunization strategy called chemovaccination. This innovative approach combines mosquito-delivered malaria parasites with an investigational class of antimalarial drug compounds. These drugs effectively obstruct the parasite's development at a crucial stage of the malaria lifecycle, preventing illness and stimulating a robust immune response that provides durable protection against malaria.

Post-chemovaccination, subsequent mosquito bites reinforce this immunity, effectively transforming mosquito bites into ongoing immune boosters.

This groundbreaking approach was demonstrated to protect mice against malaria for the entirety of the study period, a remarkable outcome with the potential to inform the development of next-generation prevention strategies for one of the world's deadliest infectious diseases. The research, published in the prestigious journal Science, is the first to target malaria parasites at the late liver stage using an antimalarial drug candidate discovered by WEHI and the global biopharmaceutical company MSD, the trade name of Merck & Co., Inc.

The WEHI researchers utilized a novel drug compound, WM382 and MK-7602, to halt the parasites just before they could cause illness, while simultaneously exposing the immune system to a broader spectrum of potential threats. This strategy required a minimal parasite dose but generated a more extensive and enduring immune response than most existing vaccine approaches.

Crucially, it also promoted the production of liver-resident memory T cells, which have the potential to swiftly identify and eliminate future infections before disease develops.

The antimalarial drug candidates employed in the study, WM382 and MK-7602, are dual inhibitors of plasmepsin IX and X, two key "master regulators" essential for parasite survival. Both compounds have emerged from a decade-long research collaboration between WEHI and MSD. John A. McCauley, MSD's senior director of discovery chemistry, noted that current approaches typically rely on genetically attenuated parasites, which, while providing strong protection, necessitate high doses and are difficult to produce, scale, and administer in real-world settings.

By contrast, the chemovaccination approach enables a more extensive immune response using a smaller parasite dose, potentially providing broader protection against the diverse array of malaria parasites encountered in real-world conditions.